AAV-Mediated Pendrin Gene Delivery for Inner Ear Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hearing loss, particularly sensorineural hearing loss, lack effective methods for repairing or mitigating the underlying causes, such as damage to inner ear hair cells, and there is a need for innovative approaches like gene therapy to restore hearing function.
Innovation Solution
The use of AAV particles carrying SLC26A4 gene constructs to express pendrin protein, which is essential for the development and maintenance of inner ear cells, delivered via surgical intervention to the inner ear, aiming to treat hearing loss by promoting the function and regeneration of hair and supporting cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for sensorineural hearing loss are used, then current standard of care is maintained, but effective repair or mitigation of underlying causes is not achieved
Solution Approach 1:
The patent uses AAV vectors as intermediary carriers to deliver the SLC26A4 gene construct to inner ear cells. The AAV particle serves as a mediator between the genetic material and the target cells, enabling safe and efficient gene delivery without direct manipulation of the cells themselves. This resolves the contradiction by providing a reliable treatment mechanism while maintaining manageable complexity through the use of a well-characterized viral vector system.
Solution Approach 2:
The gene therapy approach enables the inner ear cells to self-repair by expressing the functional SLC26A4 protein themselves. The delivered gene construct allows target cells to produce the missing or defective pendrin protein, restoring their own function without requiring continuous external intervention. This self-service mechanism improves treatment reliability while reducing long-term complexity.
2Reliability
If gene therapy approaches are implemented to restore hearing function, then effective treatment of underlying causes is achieved, but treatment complexity increases
Solution Approach 1:
The gene delivery system is segmented into distinct functional components: the SLC26A4 gene construct (containing coding sequence and regulatory elements), the AAV vector backbone, and the capsid proteins. This segmentation allows each component to be optimized independently and facilitates manufacturing and quality control, thereby reducing overall system complexity while maintaining hearing restoration capability.
Solution Approach 2:
The AAV vector platform serves multiple functions: it protects the genetic material during delivery, enables targeted transduction of inner ear cells, and provides long-term gene expression. This multi-functionality consolidates several required capabilities into a single delivery system, improving hearing restoration potential without proportionally increasing complexity.
3Reliability
If AAV particles are used to deliver SLC26A4 gene constructs, then pendrin protein expression is restored, but surgical intervention is required for delivery
Solution Approach 1:
The gene delivery is localized specifically to the inner ear compartment through surgical injection. The AAV particles are delivered directly into the cochlear space or endolymphatic sac, ensuring high local concentration at the target site while minimizing systemic exposure. This local delivery approach maximizes gene expression restoration in the relevant tissue while reducing overall procedural complexity compared to systemic administration.
Data Source
AI summary
The present disclosure provides constructs comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a pendrin protein. Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and/or deafness.